A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

(2019) Hathaichanok Phuengkham et al.   ADVANCED MATERIALS

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity

(2019) Jianshu Wei et al.   Journal for ImmunoTherapy of Cancer

Implantable Synthetic Immune Niche for Spatiotemporal Modulation of Tumor-Derived Immunosuppression and Systemic Antitumor Immunity: Postoperative Immunotherapy

(2018) Hathaichanok Phuengkham et al.   ADVANCED MATERIALS

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy

(2018) Chao Wang et al.   Science Translational Medicine

Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages

(2018) Defne Bayik et al.   Frontiers in Immunology

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

(2018) Christopher B. Rodell et al.   Nature Biomedical Engineering

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

(2017) Leisha A. Emens et al.   EUROPEAN JOURNAL OF CANCER

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Dameshek W. Chronic lymphocytic leukemia--an accumulative disease of immunologically incompetent lymphocytes. Blood. 1967;29(4):566-584.

(2016)   BLOOD

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Bioresponsive materials

(2016) Yue Lu et al.   Nature Reviews Materials

Macrophage silica nanoparticle response is phenotypically dependent

(2015) Heather L. Herd et al.   BIOMATERIALS

Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells

(2015) Jing Wang et al.   JOURNAL OF IMMUNOLOGY

In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf

(2015) Linda Hammerich et al.   Molecular Oncology

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells

(2012) Y. Shirota et al.   JOURNAL OF IMMUNOLOGY

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

(2012) J. Predina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Surgery induced immunosuppression

(2010) Brian V. Hogan et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Currently approved prophylactic HPV vaccines

(2009) Diane M Harper   Expert Review of Vaccines

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY